Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Delix Therapeutics

Delix Therapeutics Announces Positive Efficacy Data for DLX-001 (Zalsupindole) and FDA Clearance of Phase II Trial Design Featuring At‑Home Administration
From Delix Therapeutics
Via Business Wire
Delix Therapeutics Study Demonstrates that the Non‑Hallucinogenic Neuroplastogen Zalsupindole Promotes Neuroplasticity Like Ketamine and Psychedelics
From Delix Therapeutics
Via Business Wire
Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting
From Delix Therapeutics
Via Business Wire
Delix Therapeutics Announces Dosing of First Patient in Phase 1b Clinical Trial for DLX-001 in Major Depressive Disorder
From Delix Therapeutics
Via Business Wire
Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Loss
From Delix Therapeutics
Via Business Wire
Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial
From Delix Therapeutics
Via Business Wire
Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders
From Delix Therapeutics
Via Business Wire
Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting
From Delix Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.